[go: up one dir, main page]

WO1995018606A1 - Curcumine, ses analogues et leurs nouvelles utilisations - Google Patents

Curcumine, ses analogues et leurs nouvelles utilisations Download PDF

Info

Publication number
WO1995018606A1
WO1995018606A1 PCT/US1995/000104 US9500104W WO9518606A1 WO 1995018606 A1 WO1995018606 A1 WO 1995018606A1 US 9500104 W US9500104 W US 9500104W WO 9518606 A1 WO9518606 A1 WO 9518606A1
Authority
WO
WIPO (PCT)
Prior art keywords
sep
acid
curcumin
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/000104
Other languages
English (en)
Other versions
WO1995018606A9 (fr
Inventor
Bharat B. Aggarwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Priority to AU15585/95A priority Critical patent/AU687509B2/en
Priority to EP95907307A priority patent/EP0738143A1/fr
Priority to JP7518587A priority patent/JPH10500657A/ja
Publication of WO1995018606A1 publication Critical patent/WO1995018606A1/fr
Anticipated expiration legal-status Critical
Publication of WO1995018606A9 publication Critical patent/WO1995018606A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Nouvelles méthodes de traitement de maladies caractérisées par la prolifération pathologique de cellules, consistant à administrer à un animal une dose à efficacité pharmacologique de curcumine ou de l'un de ses analogues, nouvelle méthode d'inhibition de l'activité de la phosphorylase kinase et de la tyrosine kinase, et nouvelle méthode de traitement des maladies caractérisées par la prolifération pathologique de cellules consistant à administrer une dose à efficacité pharmacologique de flavonoïde.
PCT/US1995/000104 1994-01-06 1995-01-05 Curcumine, ses analogues et leurs nouvelles utilisations Ceased WO1995018606A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU15585/95A AU687509B2 (en) 1994-01-06 1995-01-05 Curcumin, analogues of curcumin and novel uses thereof
EP95907307A EP0738143A1 (fr) 1994-01-06 1995-01-05 Curcumine, ses analogues et leurs nouvelles utilisations
JP7518587A JPH10500657A (ja) 1994-01-06 1995-01-05 クルクミン、クルクミン類似体、およびそれらの新しい使用法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17803394A 1994-01-06 1994-01-06
US08/178,033 1994-01-06
US19808894A 1994-02-17 1994-02-17
US08/198,088 1994-02-17

Publications (2)

Publication Number Publication Date
WO1995018606A1 true WO1995018606A1 (fr) 1995-07-13
WO1995018606A9 WO1995018606A9 (fr) 1997-05-22

Family

ID=26873885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/000104 Ceased WO1995018606A1 (fr) 1994-01-06 1995-01-05 Curcumine, ses analogues et leurs nouvelles utilisations

Country Status (6)

Country Link
EP (1) EP0738143A1 (fr)
JP (1) JPH10500657A (fr)
AU (1) AU687509B2 (fr)
CA (1) CA2180477A1 (fr)
IL (1) IL112205A0 (fr)
WO (1) WO1995018606A1 (fr)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833629A4 (fr) * 1995-06-19 1998-09-16 Ontogen Corp Derives d'acide aryl-acrylique convenant comme inhibiteurs de proteine-tyrosine-phosphatase
JP2933511B2 (ja) 1995-07-28 1999-08-16 呉羽化学工業株式会社 フェルラ酸含有ｈｓｐ４７合成抑制剤
WO2000047205A1 (fr) * 1999-02-10 2000-08-17 The Trustees Of The University Of Pennsylvania Inhibiteurs de tyrosine-kinases et methodes d'utilisation de tels inhibiteurs
WO2000061162A1 (fr) * 1999-04-09 2000-10-19 Sabinsa Corporation Utilisation de tetrahydrocurcuminoides pour la regulation d'evenements physiologiques et pathologiques au niveau de la peau et des muqueuses
WO2000070949A1 (fr) * 1999-05-20 2000-11-30 Heng Madalene C Y Methode d'utilisation de curcumin soluble pour inhiber une phosphorylase kinase dans des maladies inflammatoires
WO2001000201A1 (fr) * 1999-06-30 2001-01-04 Emory University Inhibition de l'angiogenese grace a l'utilisation de curcumine et de curcuminoides
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
WO2002002582A1 (fr) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Derives de curcumine a solubilite dans l'eau amelioree vis-a-vis de la curcumine, et medicaments renfermant ces derives
DE19821971C2 (de) * 1998-05-18 2003-02-06 Ulti Med Products Deutschland Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
US6653327B2 (en) 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
EP1027045A4 (fr) * 1997-10-31 2004-12-08 Arch Dev Corp Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
EP1494993A4 (fr) * 2002-04-17 2005-09-14 Univ North Carolina Nouveaux analogues de curcumine et utilisations de ces derniers
WO2006097744A3 (fr) * 2005-03-17 2007-02-01 Imp Innovations Ltd Composes
WO2006087759A3 (fr) * 2005-02-21 2007-02-08 Safi Invest Holding Ag Composition pharmaceutique comprenant de la curcumine et du resveratrol et leurs utilisations dans le domaine medical
WO2007098504A1 (fr) * 2006-02-24 2007-08-30 Emory University Promedicaments d'analogues de curcumine
WO2007112855A1 (fr) * 2006-03-30 2007-10-11 Unilever Plc Agents, compositions et procedes eclaircissant la peau
EP1411959A4 (fr) * 2001-07-17 2007-12-19 Metaproteomics Llc Compositions de curcuminoides presentant une inhibition synergique de l'expression et/ou de l'activite de la cyclooxygenase-2
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1694335A4 (fr) * 2003-08-26 2008-12-31 Res Dev Foundation Inhibiteurs d'osteoclastogenese et leurs utilisations
WO2009073050A3 (fr) * 2007-07-27 2009-10-01 Research Foundation Of City University Of New York Utilisation de la curcumine pour bloquer la formation de tumeur cérébrale in vivo
WO2009101263A3 (fr) * 2008-02-15 2009-10-15 Novobion Oy Complexes solubles de la curcumine
EP2359820A1 (fr) 2010-01-29 2011-08-24 Codman & Shurtleff, Inc. Fourniture en dérivation de curcuma pour le traitement de Alzheimer
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
US8647681B2 (en) 2001-06-01 2014-02-11 Mars, Inc. Skin diet
US8648102B2 (en) 2003-12-11 2014-02-11 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
EP2749552A1 (fr) 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Hybrides curcumine-resvératrol
CN105669788A (zh) * 2016-03-18 2016-06-15 昆明理工大学 一种从竹笋中提取活性化合物的方法及其应用
WO2020239948A1 (fr) 2019-05-28 2020-12-03 Isanas Ag Agoniste du récepteur μ-opioïde à action centrale en association avec un curcuminoïde s'utilisant dans le traitement d'une tumeur du système nerveux central
US10875841B2 (en) 2018-08-29 2020-12-29 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
US11312676B2 (en) 2014-12-30 2022-04-26 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1496880A4 (fr) * 2002-04-24 2007-12-12 Res Dev Foundation EFFETS SYNERGETIQUES DES INHIBITEURS DU FACTEUR NF-kB DE TRANSCRIPTION NUCLEAIRE ET D'AGENTS ANTI-CANCEREUX
PH12022550608A1 (en) * 2019-09-17 2023-01-23 Enzene Biosciences Ltd Compositions for use in inhibiting src kinase and treating and preventing associated disorders
CN116407527A (zh) * 2023-01-04 2023-07-11 河南科技大学第一附属医院 咖啡酸的应用以及用于预防和治疗口腔鳞癌的药物

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3777037A (en) * 1970-09-22 1973-12-04 Us Agriculture Cinnamyl phenols useful as anti-microbial agents
JPS5045660A (fr) * 1973-08-25 1975-04-23
JPS57185219A (en) * 1981-05-12 1982-11-15 Chugai Pharmaceut Co Ltd Remedy for cancer
US4421927A (en) * 1980-10-23 1983-12-20 Societe De Recherches Industrielles (S.O.R.I.) New cinnamoyl-cinnamic acid derivative, and its use as pharmaceutical
US4733002A (en) * 1984-05-23 1988-03-22 Green Cross Corporation Lipoxygenase inhibitor
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5238832A (en) * 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids
US5288750A (en) * 1988-09-01 1994-02-22 Orion-Yhtyma Oy Substituted β-diketones

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3777037A (en) * 1970-09-22 1973-12-04 Us Agriculture Cinnamyl phenols useful as anti-microbial agents
JPS5045660A (fr) * 1973-08-25 1975-04-23
US4421927A (en) * 1980-10-23 1983-12-20 Societe De Recherches Industrielles (S.O.R.I.) New cinnamoyl-cinnamic acid derivative, and its use as pharmaceutical
JPS57185219A (en) * 1981-05-12 1982-11-15 Chugai Pharmaceut Co Ltd Remedy for cancer
US4733002A (en) * 1984-05-23 1988-03-22 Green Cross Corporation Lipoxygenase inhibitor
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US4904697A (en) * 1987-04-09 1990-02-27 Merrell Dow Pharmaceuticals Inc. Controlling the growth of certain tumor tissue with chalcone derivatives
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5288750A (en) * 1988-09-01 1994-02-22 Orion-Yhtyma Oy Substituted β-diketones
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5238832A (en) * 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEM. ABS., Vol. 107, issued 1987, NISHNO et al., "Antitumor-Promoting Activity of Curcumin, a Major Constituent of the Food Additive Tumeric Yellow", No. 211555. *
CHEM. ABS., Vol. 109, issued 1988, HUANG M.T. et al., "Inhibitory Effect of Curcumin, Chlorogenic Acid, Caffeic Acid, and Ferulic Acid on Tumor Promotion in Mouse Skin by 12-0-Tetradecanoylphorbol-13-Acetate", No. 220060. *
CHEM. ABS., Vol. 110, issued 1989, RAO et al., "Antitumor Acitvity of Phenyl Substituted Cinnamoylmethanes", No. 165550. *
CHEM. ABS., Vol. 113, issued 1990, SOUDAMINI et al., "Cytotoxic and Tumor Reducing Properties of Curcumin", No. 29203. *
CHEM. ABS., Vol. 114, issued 1991, HUANG M.T. et al., II, "Inhibitory Effects of Curcumin on In Vitro Lipoxygenase and Cyclooxygenase Activities in Mouse Epidermis", No. 114763. *
CHEM. ABS., Vol. 115, issued 1991, HUANG T.S. et al., "Suppression of C-Jun/AP-1 Activation by an Inhibitor of Tumor Promotion in Mouse Fibroblast Cells", No. 43302. *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833629A4 (fr) * 1995-06-19 1998-09-16 Ontogen Corp Derives d'acide aryl-acrylique convenant comme inhibiteurs de proteine-tyrosine-phosphatase
JP2933511B2 (ja) 1995-07-28 1999-08-16 呉羽化学工業株式会社 フェルラ酸含有ｈｓｐ４７合成抑制剤
EP1027045A4 (fr) * 1997-10-31 2004-12-08 Arch Dev Corp Procedes et compositions pour reguler l'activite de la 5-alpha-reductase
DE19821971C2 (de) * 1998-05-18 2003-02-06 Ulti Med Products Deutschland Arzneimittel zur Behandlung von Psoriasis oder Neurodermitis
WO2000047205A1 (fr) * 1999-02-10 2000-08-17 The Trustees Of The University Of Pennsylvania Inhibiteurs de tyrosine-kinases et methodes d'utilisation de tels inhibiteurs
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6653327B2 (en) 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
WO2000061162A1 (fr) * 1999-04-09 2000-10-19 Sabinsa Corporation Utilisation de tetrahydrocurcuminoides pour la regulation d'evenements physiologiques et pathologiques au niveau de la peau et des muqueuses
WO2000070949A1 (fr) * 1999-05-20 2000-11-30 Heng Madalene C Y Methode d'utilisation de curcumin soluble pour inhiber une phosphorylase kinase dans des maladies inflammatoires
WO2001000201A1 (fr) * 1999-06-30 2001-01-04 Emory University Inhibition de l'angiogenese grace a l'utilisation de curcumine et de curcuminoides
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
EP1196158A4 (fr) * 1999-06-30 2004-05-26 Univ Emory Inhibition de l'angiogenese grace a l'utilisation de curcumine et de curcuminoides
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
WO2002002582A1 (fr) * 2000-06-30 2002-01-10 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Derives de curcumine a solubilite dans l'eau amelioree vis-a-vis de la curcumine, et medicaments renfermant ces derives
US8647681B2 (en) 2001-06-01 2014-02-11 Mars, Inc. Skin diet
EP1411959A4 (fr) * 2001-07-17 2007-12-19 Metaproteomics Llc Compositions de curcuminoides presentant une inhibition synergique de l'expression et/ou de l'activite de la cyclooxygenase-2
US8198323B2 (en) 2002-04-17 2012-06-12 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1494993A4 (fr) * 2002-04-17 2005-09-14 Univ North Carolina Nouveaux analogues de curcumine et utilisations de ces derniers
US7355081B2 (en) 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
AU2003222087B2 (en) * 2002-04-17 2008-08-21 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
AU2003222087B8 (en) * 2002-04-17 2008-09-04 University Of North Carolina At Chapel Hill Novel curcumin analogues and uses thereof
US7709535B2 (en) 2003-03-27 2010-05-04 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
EP1694335A4 (fr) * 2003-08-26 2008-12-31 Res Dev Foundation Inhibiteurs d'osteoclastogenese et leurs utilisations
US9096499B2 (en) 2003-12-11 2015-08-04 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
US8648102B2 (en) 2003-12-11 2014-02-11 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
WO2006087759A3 (fr) * 2005-02-21 2007-02-08 Safi Invest Holding Ag Composition pharmaceutique comprenant de la curcumine et du resveratrol et leurs utilisations dans le domaine medical
WO2006097744A3 (fr) * 2005-03-17 2007-02-01 Imp Innovations Ltd Composes
WO2007098504A1 (fr) * 2006-02-24 2007-08-30 Emory University Promedicaments d'analogues de curcumine
WO2007112855A1 (fr) * 2006-03-30 2007-10-11 Unilever Plc Agents, compositions et procedes eclaircissant la peau
KR101390058B1 (ko) 2006-03-30 2014-04-29 유니레버 엔.브이. 피부 미백제, 조성물 및 방법
AU2007234455B2 (en) * 2006-03-31 2012-10-04 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US8779151B2 (en) 2006-03-31 2014-07-15 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
EP2749552A1 (fr) 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Hybrides curcumine-resvératrol
WO2009073050A3 (fr) * 2007-07-27 2009-10-01 Research Foundation Of City University Of New York Utilisation de la curcumine pour bloquer la formation de tumeur cérébrale in vivo
US8568815B2 (en) 2008-02-15 2013-10-29 Novobion Oy Soluble complexes of curcumin
WO2009101263A3 (fr) * 2008-02-15 2009-10-15 Novobion Oy Complexes solubles de la curcumine
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
US9000179B2 (en) 2008-07-08 2015-04-07 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
EP2359820A1 (fr) 2010-01-29 2011-08-24 Codman & Shurtleff, Inc. Fourniture en dérivation de curcuma pour le traitement de Alzheimer
US11312676B2 (en) 2014-12-30 2022-04-26 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
CN105669788A (zh) * 2016-03-18 2016-06-15 昆明理工大学 一种从竹笋中提取活性化合物的方法及其应用
US10875841B2 (en) 2018-08-29 2020-12-29 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
US11708350B2 (en) 2018-08-29 2023-07-25 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
US12338229B2 (en) 2018-08-29 2025-06-24 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
WO2020239948A1 (fr) 2019-05-28 2020-12-03 Isanas Ag Agoniste du récepteur μ-opioïde à action centrale en association avec un curcuminoïde s'utilisant dans le traitement d'une tumeur du système nerveux central

Also Published As

Publication number Publication date
CA2180477A1 (fr) 1995-07-13
AU1558595A (en) 1995-08-01
IL112205A0 (en) 1995-03-15
JPH10500657A (ja) 1998-01-20
EP0738143A1 (fr) 1996-10-23
AU687509B2 (en) 1998-02-26

Similar Documents

Publication Publication Date Title
AU687509B2 (en) Curcumin, analogues of curcumin and novel uses thereof
WO1995018606A9 (fr) Curcumine, ses analogues et leurs nouvelles utilisations
Kadekaro et al. α-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes
Thaloor et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin
US5541232A (en) Treatment of multidrug resistant diseases
Khodamoradi et al. Targets for protection and mitigation of radiation injury
Das et al. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFκB
Soter et al. Local effects of synthetic leukotrienes (LTC4, LTD4, and LTB4) in human skin
Zhou et al. Cardioprotective effect of water and ethanol extract of Salvia miltiorrhiza in an experimental model of myocardial infarction
US5871779A (en) Treatment of arthropathies with vanadate compounds or analogues thereof
Lee et al. α‐Mangostin, a novel dietary xanthone, suppresses TPA‐mediated MMP‐2 and MMP‐9 expressions through the ERK signaling pathway in MCF‐7 human breast adenocarcinoma cells
Velasco et al. Dermatological aspects of angiogenesis
CA2377141A1 (fr) Inhibition de l'angiogenese grace a l'utilisation de curcumine et de curcuminoides
Figg et al. The pharmacokinetics of TNP‐470, a new angiogenesis inhibitor
Zhang et al. Suppressing BRD4 exhibits protective effects against vincristine-induced peripheral neuropathy by alleviating inflammation and oxidative stress
Yang et al. Cerebral ischemia/reperfusion injury and pharmacologic preconditioning as a means to reduce stroke-induced inflammation and damage
ZA200407182B (en) Dexanabinol and dexanabinol analogs regulate inflammation releated genes.
Sinch et al. Calcium glucarate prevents tumor formation in mouse skin
Cuzzocrea et al. Superoxide-related signaling cascade mediates nuclear factor-κB activation in acute inflammation
Samuels et al. Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice
KR101542774B1 (ko) 리그난 유도체를 함유하는 세라마이드 대사관련 효소에 의해 매개되는 질환의 예방 또는 치료용 조성물
Bedoya et al. The role of parthenolide in intracellular signalling processes: review of current knowledge
CN100370981C (zh) 毛萼乙素在制药中的应用
Matos et al. Sesquiterpene lactones: promising natural compounds to fight inflammation. Pharmaceutics. 2021; 13 (7): 991
Spath et al. Diethyldithiocarbamate inhibits scheduled and unscheduled DNA synthesis of rat thymocytes in vitro and in vivo—dose-effect relationships and mechanisms of action

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN FI JP KR NO NZ RU US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2180477

Country of ref document: CA

Ref document number: 279068

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995907307

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995907307

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 31,AMENDED CLAIMS,ADDED

WWW Wipo information: withdrawn in national office

Ref document number: 1995907307

Country of ref document: EP